Is going into stable symptomatic remission associated with a more positive development of life satisfaction? A 10-year follow-up study of first episode psychosis
Gardsjord, Erlend Strand; Romm, Kristin Lie; Røssberg, Jan Ivar; Friis, Svein; Barder, Helene Eidsmo; Evensen, Julie; Haahr, Ulrik; ten Velden Hegelstad, Wenche; Joa, Inge; Johannessen, Jan Olav; Langeveld, Johannes; Larsen, Tor Ketil; Opjordsmoen, Stein; Rund, Bjørn Rishovd; Simonsen, Erik; Vaglum, Per; McGlashan, Thomas; Melle, Ingrid
(2018) Schizophrenia Research, volume 193, pp. 364 - 369
(Article)
Abstract
Background: Quality of life is an important outcome measure for patients with psychosis. We investigated whether going into stable symptomatic remission is associated with a more positive development of subjective quality of life (S-QoL) and if different patient characteristics are associated with S-QoL depending on remission status. Methods: Three hundred
... read more
and one patients with a first-episode psychosis were included at baseline. At 10-year follow-up 186 were reassessed. QoL was assessed by Lehman's Quality of Life Interview. Remission was defined according to criteria proposed by the Remission in Schizophrenia Working Group. One-way ANOVA, mixed model analysis, bivariate correlations and multiple regression analyses were performed. Results: Patients going into stable symptomatic remission showed a more positive S-QoL-development over the follow-up period and reported higher life satisfaction at 10-year follow-up compared to non-remission. At 10-year follow-up, depressive symptoms and alcohol abuse or dependence explained a significant amount of variance in S-QoL among patients in remission. Among patients in non-remission, PANSS excitative component explained a significant amount of variance in S-QoL. All significant effects were negative. Conclusions: Stable symptomatic remission is associated with a more positive development of overall life satisfaction. Furthermore, different symptoms influence life satisfaction depending on status of remission. This has important clinical implications. While patients in remission might need treatment for depressive symptoms to increase S-QoL, in non-remission measures aiming to decrease hostility and uncooperativeness should be part of the treatment approach. Alcohol problems should be treated regardless of remission status.
show less
Download/Full Text
The full text of this publication is not available.
Keywords: First episode psychosis, Life satisfaction, Long-term follow-up, Quality of life, Remission, Schizophrenia, Humans, Middle Aged, Male, Quality of Life/psychology, Personal Satisfaction, Young Adult, Regression Analysis, Psychiatric Status Rating Scales, Analysis of Variance, Adolescent, Adult, Female, Aged, Psychotic Disorders/psychology, Longitudinal Studies, Psychiatry and Mental health, Biological Psychiatry, Research Support, Non-U.S. Gov't, Journal Article, Research Support, N.I.H., Extramural
ISSN: 0920-9964
Publisher: Elsevier
Note: Funding Information: The project has been approved by the Regional Committee for Medical Research Ethics Health Region II (#S-95189) and the Regional Committee for Medical Research Ethics Health Region East (#1.2007.2177). Data Inspectorate (License #96/3017-2 and #2003/2052). Biological data collection approved by Norwegian Directory of Health (#200403453) and the Regional Committee for Medical Research Ethics Health Region East (#493-03-01179). The Regional Committee for Science Ethics region Sjælland, Denmark (#1-01-83-0002-07). Supported by Health West, Norway (Wenche ten Velden Hegelstad) (# 911369 ); supported by the Norwegian National Research Council (# 133897/320 and # 154642/320 ), the Norwegian Department of Health and Social Affairs , and the National Council for Mental Health/Health and Rehabilitation (# 1997/41 and # 2002/306 ), Rogaland County and Oslo County (Drs. Vaglum, Johannessen, Friis, Larsen, Melle, Opjordsmoen). Also funded by the Theodore and Vada Stanley Foundation , the Regional Health Research Foundation for Eastern Region, Denmark ; Roskilde County, Helsefonden, Lundbeck Pharma , Eli Lilly and Janssen-Cilag Pharmaceuticals , Denmark (Drs Simonsen and Haahr). Also supported by a National Alliance for Research on Schizophrenia and Depression ( NARSAD ) Distinguished Investigator Award and NIMH grant MH-01654 (Dr. McGlashan) and a NARSAD Young Investigator Award (Dr. Larsen). Health South East (# 2008001 ), Health West (# 200202797-65 ) (Inge Joa) and Regional Centre for Clinical Research in Psychosis (# 911313 ). Publisher Copyright: © 2017
(Peer reviewed)